AstraZeneca Pledges $50B U.S. Manufacturing Expansion by 2030 with New Virginia Plant
AZN•AstraZeneca will invest $50 billion in U.S. manufacturing by 2030, funding a new drug substance facility in Virginia and expansions in five states including Maryland and California. The company has initiated technology transfers and inventory management measures to avoid impending 100% tariffs, anticipating minimal disruption.
1. Investment Scope
AstraZeneca announced a $50 billion investment in U.S. manufacturing by 2030, including a new drug substance facility in Virginia and expansions across Maryland, Massachusetts, California, Indiana and Texas. This represents the company’s largest single‐site global investment and underscores its commitment to domestic production capacity.
2. Tariff Mitigation Strategy
To mitigate potential 100% tariffs on branded drugs, AstraZeneca has begun technology transfers and stocked U.S. inventory for 2025, with executives indicating that these measures should limit any disruption to operations and supply chains.
